Bladder Cancer Surgery

(Source: BJU International) Source: MedWorm: Bladder Cancer

In conclusion, our results suggest that TGFalpha overexpression in mouse urogenital organs alone may not be responsible for tumor formation and epithelial hyperplasia, but is involved in bladder outlet obstruction.
PMID: 20638776 [PubMed - as supplied by publisher] (Source: Differentiation)

Source: MedWorm: Bladder Cancer

CONCLUSIONS: VEGFR-2 and VEGFR-3 are primarily localized to, and significantly upregulated on, tumor vasculature (blood and/or lymphatic) supporting the majority of solid cancers. The primary clinical mechanism of action of VEGF signaling inhibitors is likely to be through the targeting of tumor vessels rather than tumor cells. The upregulation of VEGFR-3 on tumor blood vessels indicates a potential additional antiangiogenic effect for dual VEGFR-2/VEGFR-3-targeted therapy. Clin Cancer Res; 16(14); 3548-61. (c)2010 AACR.
PMID: 20606037 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research) Source: MedWorm: Bladder Cancer

Summary  The effects of combined RNA interference (RNAi) of human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT)
genes on telomerase activity in a bladder cancer cell line (BIU-87 cells) were investigated by using gene chip technology
in vitro with an attempt to evaluate the role of RNAi in the gene therapy of bladder transitional cell cancer (BTCC). Three TR-specific
double-stranded small interfering RNAs (siRNAs) and three TERT-specific double-stranded siRNAs were designed to target different
regions of TR and TERT mRNA. The phTR-siRNA, phTERT-siRNA, and the combination of both plasmids phTR+phTERT-siRNA were transfected
into BIU-87 cells. The expression of hTR and hTERT mRNA was detected by quantitative fluorescent reverse transcription-polymerase… Source: MedWorm: Bladder Cancer

Authors: Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, Safe S
Arsenic trioxide exhibits antiproliferative, antiangiogenic and proapoptotic activity in cancer cells, and many genes associated with these responses are regulated by specificity protein (Sp) transcription factors. Treatment of cancer cells derived from urologic (bladder and prostate) and gastrointestinal (pancreas and colon) tumors with arsenic trioxide demonstrated that these cells exhibited differential responsiveness to the antiproliferative effects of this agent and this paralleled their differential repression of Sp1, Sp3 and Sp4 proteins in the same cell lines. Using arsenic trioxide responsive KU7 and non-responsive 253JB-V bladder cancer cells as models, we show that in KU7 cells, </= 5m… Source: MedWorm: Bladder Cancer

In this study, we explored the effect of combining alkylating agents and arsenic trioxide (ATO) on the suppression of tumor cells with inherited or acquired resistance to therapeutic agents. Our results showed that combining ATO and a synthetic derivative of 3a-aza-cyclopenta[a]indenes (BO-1012), a bifunctional alkylating agent causing DNA interstrand cross-links, was more effective in killing human cancer cell lines (H460, H1299, and PC3) than combining ATO and melphalan or thiotepa. We further demonstrated that the combination treatment of H460 cells with BO-1012 and ATO resulted in severe G(2)/M arrest and apoptosis. In a xenograft mouse model, the combination treatment with BO-1012 and ATO synergistically reduced tumor volumes in nude mice inoculated with H460 cells. Similarly, the com… Source: MedWorm: Bladder Cancer

Authors: T J Harvey, D Burdon, L Steele, N Ingram, G D Hall, P J Selby, R G Vile, P A Cooper, S D Shnyder
& J D Chester (Source: Gene Therapy)

Source: MedWorm: Bladder Cancer

Conclusions:
These experiments established for the first time a correlation between the level of PSCA expression and tumor growth and suggest a role of PSCA in counteracting the natural immune response. (Source: BMC Cancer) Source: MedWorm: Bladder Cancer

CONCLUSIONS: Subepithelial growth is not an uncommon in bladder cancer. It is more frequent in high-grade and high-stage tumors. The findings of this study suggest that subepithelial growth carries a higher risk for stage progression (EGP and VBNI) and mortality (EGP), but not tumor recurrence.
PMID: 20207557 [PubMed - as supplied by publisher] (Source: Urologic Oncology) Source: MedWorm: Bladder Cancer